Eli Lilly Breaks Ground on $6.5 Billion Houston Plant

Eli Lilly broke ground Monday on a $6.5 billion pharmaceutical manufacturing facility in Houston — the tenth site the company has announced in the U.S. since 2020, according to a news release.

The Indianapolis-based drugmaker is building the plant as part of a $50 billion push to reshore medicine production to the United States, the company said.

Bechtel's manufacturing and technology business unit is supporting the project, according to a job posting from the Reston, Virginia-based general contractor. Eli Lilly and Bechtel did not immediately confirm Bechtel's involvement.

A pipeline of multibillion-dollar plants

The Houston groundbreaking adds to a string of mega-scale manufacturing projects in Lilly's pipeline.

Last September, the company announced plans for a $5 billion facility outside Richmond, Virginia, focused on cancer and autoimmune treatments. In December, it unveiled a $6 billion plant in Huntsville, Alabama, set to produce weight loss medications and other pharmaceutical ingredients.

Other announced sites include Lebanon, Indiana; Concord, North Carolina; Kenosha, Wisconsin; and Lehigh Valley, Pennsylvania, according to the release.

What the Houston plant will make

Once operational, the Houston facility will manufacture active pharmaceutical ingredients for Foundayo — Lilly's first synthetic oral GLP-1 weight loss drug — along with other small-molecule medicines and advanced therapeutics, according to the news release.

The plant will run on what Lilly calls state-of-the-art technologies: machine learning, artificial intelligence, digitally integrated systems and advanced data analytics. The company plans to embed digital automation throughout the site to streamline operations and ensure quality medicines.

David Ricks, Eli Lilly's chair and CEO, framed the project as part of the company's domestic manufacturing campaign.

"We are thrilled to break ground on our latest 'medicines made in America' site in the great state of Texas," Ricks said in the release. "We will make and ship Lilly's latest products from Texas to people here at home and around the world."

With Houston now under construction, Lilly's $50 billion reshoring program continues to feed one of the largest privately driven industrial construction pipelines in the country, with Bechtel's role — signaled so far only through a job posting — awaiting official confirmation from either company.